Evidence map›Paper›PMID 36228594›Full record

ReviewRespiration; international review of thoracic diseases2022

Incidental Pulmonary Nodules - What Do We Know in 2022.

Gerald Schmid-Bindert, Jens Vogel-Claussen, Sylvia Gütz, Joana Fink, Hans Hoffmann, Martin E Eichhorn, Felix J F Herth

Open access · hybridAbstract readReview
In one paragraph

Review in Respiration; international review of thoracic diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Incidental Pulmonary Nodules: What Should We Do in 2026?Respiration; international review of thoracic diseases · 2026
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Gerald Schmid-BindertMedical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Jens Vogel-ClaussenDepartment of Diagnostic and Interventional Radiology, Hannover Medical School, Hannover, Germany.
Sylvia GützDepartment of Pneumology, Cardiology, Endocrinology, Diabetology and General Internal Medicine, Sankt Elisabeth Hospital, Leipzig, Germany.
Joana FinkAstraZeneca GmbH, Hamburg, Germany.
Hans HoffmannSection for Thoracic Surgery, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.
Martin E EichhornDepartment of Thoracic Surgery, Thoraxklinik, University Hospital Heidelberg, Heidelberg, Germany.
Felix J F HerthTranslational Lung Research Center (TLRC) Heidelberg, Member of the German Center for Lung Research (DZL), Heidelberg, Germany.
Heidelberg University · DEAstraZeneca (Germany) · DEMedizinische Hochschule Hannover · DESt. Elisabeth-Krankenhaus Leipzig · DETUM Klinikum · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer (LC) is the leading cause of cancer-related mortality worldwide, and early LC diagnosis can significantly improve outcomes and survival rates in affected patients. Implementation of LC screening programs using low-dose computed tomography CT in high-risk subjects aims to detect LC as early as possible, but so far, adoption of screening programs into routine clinical care has been very slow. In recent years, the use of CT has significantly increased the rate of incidentally detected pulmonary nodules. Although most of those incidental pulmonary nodules (IPNs) are benign, some of them represent early-stage LC. Given the large number of IPNs detected in the range of several millions each year, this represents an additional, maybe even larger, opportunity to drive stage shift in LC diagnosis, next to LC screening programs. Comprehensive evaluation and targeted work-up of IPNs are mandatory to identify the malignant nodules from the crowd, and several guidelines provide radiologists and physicians' guidance on IPN assessment and management. However, IPNs still seem to be inadequately processed due to various reasons including insufficient reporting in the radiological report, missing communication between stakeholders, absence of patient tracking systems, and uncertainty regarding responsibilities for the IPN management. In recent years, several approaches such as lung nodule programs, patient tracking software, artificial intelligence, and communication software were introduced into clinical practice to address those shortcomings. This review evaluates the current situation of IPN management and highlights recent developments in process improvement to achieve first steps toward stage shift in LC diagnosis.

Indexed as

Lung NeoplasmsMultiple Pulmonary NodulesSolitary Pulmonary NoduleArtificial IntelligenceEarly Detection of CancerHumansIncidental FindingsTomography, X-Ray ComputedEarly-stage diagnosisIncidental pulmonary nodulesLow-dose computed tomographyLung cancer screeningLung nodule managementStage shift

Identifiers

PMID36228594
PMCPMC9945197
OpenAlexW4306154178

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.